GO Term | Evidence Code | PMID |
---|---|---|
positive regulation of MAP kinase activity | ||
adaptive immune response |
|
|
sphingosine-1-phosphate receptor signaling pathway | ||
G protein-coupled receptor signaling pathway | ||
cell migration |
GO Term | Evidence Code | PMID |
---|---|---|
kinase activity | ||
ephrin receptor binding | ||
1-phosphatidylinositol-3-kinase activity | ||
protein serine/threonine kinase activity | ||
protein serine kinase activity |
DO ID | Disease Name | Source |
---|---|---|
DOID:0050741 | alcohol dependence | |
DOID:0050745 | diffuse large B-cell lymphoma | |
DOID:0050746 | mantle cell lymphoma | |
DOID:0050747 | obsolete lymphoplasmacytic lymphoma | |
DOID:0050749 | peripheral T-cell lymphoma | |
DOID:0050753 | cerebellar ataxia | |
DOID:0050757 | deafness-dystonia-optic neuronopathy syndrome | |
DOID:0050759 | myotonic dystrophy type 2 | |
DOID:0050765 | neuroacanthocytosis | |
DOID:0050766 | choreaacanthocytosis |
HPO ID | HPO Term |
---|---|
HP:0000007 | Autosomal recessive inheritance |
HP:0000010 | Recurrent urinary tract infections |
HP:0000403 | Recurrent otitis media |
HP:0000964 | Eczematoid dermatitis |
HP:0001252 | Hypotonia |
HP:0001433 | Hepatosplenomegaly |
HP:0001581 | Recurrent skin infections |
HP:0001742 | Nasal congestion |
HP:0001744 | Splenomegaly |
HP:0001873 | Thrombocytopenia |
Disease ID | Disease Name |
---|---|
OMIM:619802 |
|
Species | Gene ID | Alliance of Genome Resources | Orthologous MAtrix |
---|---|---|---|
174762 | WB:WBGene00000090 | ||
100180112 | CIOIN10552 | ||
103175665 | CALMI07698 | ||
102353565 | LATCH06525 | ||
406598 | ZFIN:ZDB-GENE-040426-2532 | DANRE34488 | |
103041836 | ASTMX20676 | ||
108279798 | ICTPU12268 | ||
113575802 | ELEEL16633 | ||
106576084 | SALSA52429 | ||
106609208 | SALSA135073 |
GlyCosmos is a member of the GlySpace Alliance together with GlyGen and Glycomics@ExPASy.
Supported by JST NBDC Grant Number JPMJND2204
Partly supported by NIH Common Fund Grant #1U01GM125267-01
GlyCosmos Portal v4.0.0
Last updated: August 19, 2024